Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nizubaglustat in Gaucher Disease Type 3
NCT07715084Phase 2Not yet recruiting
- Sponsor
- Azafaros
- Start
- Sep 2026
- Primary completion
- Jan 2028
- Countries
- 3
01
Overview
A Phase 2 trial of nizubaglustat in Gaucher disease type 3, sponsored by Azafaros. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
nizubaglustat
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on NCT07715084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07715084.